Colorectal cancer (CRC) is a major public health problem. Men have a 1 in 16 and women have a 1 in 20 lifetime risk of being diagnosed with CRC. In 2007--2008, there were ∼17 100 new cases diagnosed in men and 14 400 in women, making it the third most commonly diagnosed cancer (excluding non-melanoma skin cancers) in the United Kingdom (UK). In the same year, ∼13 300 people died from CRC, the second highest cause of cancer mortality in the UK ([@bib5]).

The NHS Bowel Cancer Screening Programme (BCSP) was introduced in April 2006 in order to decrease population mortality from CRC. The primary aim of the programme is to detect CRC at an earlier stage, thereby improving survival ([@bib16]). A secondary aim is to identify and remove colorectal adenomas.

In the North East of England, full uptake of the screening programme was achieved by April 2008. The population eligible for screening included anyone aged 60--69 years, extended to 74 years in January 2010. Screening comprises biennial non-rehydrated guaiac-based faecal occult blood tests (FOBt; Hema-Screen, Immunostics Inc.). For those with positive results, a colonoscopy is offered ([@bib16]). Those with a negative FOBt are re-invited to undergo FOB testing in 2 years\' time.

We have previously reported a comparison of screen-detected and interval CRCs diagnosed after a positive or negative BCSP FOB testing, respectively ([@bib8]). Interval CRCs (defined as a cancer diagnosed after a negative screening episode, before the next planned screening test) have been shown by this and other studies to be more commonly found in women and to be located in the right colon ([@bib21]; [@bib14]). As nearly 40% of screen-detected cancers are Dukes\' Stage A, it has been presumed that it is the early tumour stage which influences the survival rate compared with the interval cancer group. It is not known whether interval cancers are *de novo* lesions following a true negative screening test, or represent a false negative test or further investigation of a 'missed\' lesion ([@bib6]). Interval CRCs are more frequently found in the right colon, and are often sessile, making them harder to detect at colonoscopy ([@bib9]). However, interval CRCs are more likely than screen-detected CRCs to have features of microsatellite instability (MSI), as a marker of genetic instability. Lesions with MSI are associated with rapid growth, and therefore may develop between examinations. To date, studies investigating the biology of interval cancers have been based on those detected in symptomatic populations ([@bib18]; [@bib2]; [@bib19]).

The aim of this study was to analyse survival after diagnosis of individuals with a screen-detected CRC compared with individuals with an interval CRC when matched for tumour stage.

Materials and Methods
=====================

The Northern Region Colorectal Cancer Audit Group (NORCCAG) registry was interrogated to identify all patients diagnosed with a CRC between 1 April 2007 and 31 March 2010, in the screening age range of 60--69 years. These patients were cross-referenced with the regional bowel cancer screening database to obtain each patient\'s screening history. Patients were then categorised into their diagnostic category of either screen-detected or interval CRCs.

The study was classed as a service evaluation, therefore formal ethical approval was not required. The National Information Governance Board (NIGB) accepted that pseudo-anonymisation of patients between databases was sufficient for no formal approval to be required.

American Society of Anaesthesiologists (ASA) physical status grade was used as a surrogate for severity of patient\'s comorbidity, being dichotomised into grades 1--2 or 3--5 (data recorded in the NORCCAG database, and supplemented where possible from patient records). Tumour location was dichotomised as distal to the splenic flexure or proximal (up to and including the splenic flexure). Deprivation level was calculated using the participants\' postcode to derive their respective index of multiple deprivation rank (2007) for the Lower Super Output Area that they reside in. Patients were then grouped into their respective quintiles, from most affluent to most deprived. The modified Dukes\' staging classification (stages A--D) was used to stage each tumour. Local excisions included all endoscopic polypectomies and trans-anal resection of tumours. Management of all CRC cases were discussed in dedicated colorectal multidisciplinary team meetings. No *a priori* statistical analysis was performed, it was solely on the population within the defined database. Pearson\'s chi-squared tests were used for variables of gender, deprivation, ASA grade, tumour location and Dukes\' stage. The log-rank Mantel--Cox test used for survival analysis, and Cox proportional hazards regression for multivariate analysis. Survival length was calculated from date of diagnosis to death, or censored at the end of available follow-up (1 March 2012). Data were analysed using SPSS version 19.0 (SPSS Inc., Chicago, IL, USA). Significance was assumed at the 0.05 level.

Results
=======

Of 514 CRCs detected within the study period, 322 (67.6%) were screen-detected and 192 (37.4%) were interval CRCs. All interval cancers were diagnosed after an overall normal FOBt, with 15 (7.8%) interval cancers submitting one unclear FOB test first, before having two normal tests. There were no post-colonoscopy interval cancers. Mean survival length was 32.1 months (s.e.m. 0.59 months). Results are presented by modified Dukes\' stage, and are shown in [Table 1](#tbl1){ref-type="table"}.

Outcomes for Dukes\' A cancers
------------------------------

One of 36 (2.8%) of Dukes\' A interval cancers and 15 of 125 (12.0%) of screen-detected cancers were diagnosed after the incident (second round) of FOB tests. There were no significant differences found in tumour site, T stage, patient comorbidity level, or deprivation level between interval and screen-detected Dukes\' A cancers. Despite comparable T staging, there were significantly more screen-detected CRCs managed with local excision compared with interval CRCs (30.4% *vs* 11.1%). Despite this, the 30-day mortality rate and overall survival rate (on Kaplan--Meier analysis) were equivalent between screen-detected and interval Dukes\' A CRCs (log-rank Mantel--Cox *χ*^2^=2.901, df=1, *P*=0.089; [Figure 1](#fig1){ref-type="fig"}). However, there were only a small number of deaths overall in each group.

Outcomes for Dukes\' B cancers
------------------------------

One of 51 (2.0%) of Dukes\' B interval cancers and 9 of 81 (11.1%) of screen-detected cancers were diagnosed after the incident (second round) of FOB tests. When the demographics and tumour details of the Dukes\' B cancer patients were reviewed, significant differences were found in the mean age at diagnosis (*t*=2.29, *P*=0.023, although unlikely clinically significant) and T stage (*χ*^2^=4.959, df=1, *P*=0.026), both of which were greater in the interval cancer group ([Table 1](#tbl1){ref-type="table"}). Gender, ASA grade, deprivation level, tumour site, management, and 30-day mortality rate were not significantly different between screen and interval cancer groups ([Table 1](#tbl1){ref-type="table"}).

The survival rates between the two groups was equivalent (log-rank Mantel--Cox *χ*^2^=0.023, df=1, *P*=0.880; [Figure 2](#fig2){ref-type="fig"}), although there were again only a small number of deaths in each group.

Outcomes for Dukes\' C cancers
------------------------------

Three of 56 (5.4%) of Dukes\' C interval cancers and 10 of 89 (11.2%) of screen-detected cancers were diagnosed after the incident (second round) of FOB tests. Within the screen-detected cancer group, there were significantly more men (*χ*^2^=5.486, df=1, *P*=0.019) and left-sided tumours (*χ*^2^=4.723, df=1, *P*=0.030; [Table 1](#tbl1){ref-type="table"}). A greater proportion of pT4 tumours were seen in the interval cancer group (37.5% *vs* 22.5%), although this and the overall T-stage proportions were not significantly different between groups. There were no differences found in the ASA grade, deprivation level, modality of surgery, or 30-day mortality between groups.

Patients with Dukes\' C screen-detected cancers had improved survival compared to interval cancers (log-rank Mantel--Cox *χ*^2^=6.048, df=1, *P*=0.014; [Figure 3](#fig3){ref-type="fig"}).

When the proportions of C1 and C2 cancers between groups were reviewed (screen-detected C1 89.9% *vs* interval C1 87.5%), there were no significant differences found (*χ*^2^=0.2, df=1, *P*=0.66). For Dukes\' C2 cancers and combined Dukes\' C, the mean number of positive lymph nodes was significantly higher in the interval cancer group compared to the screen-detected group, as shown in [Table 2](#tbl2){ref-type="table"}.

When the survival curves were separated into Dukes\' C1 and C2 CRCs, tumour site, and gender, only screen-detected cancers of Dukes\' C2 stage had a significantly superior survival curve compared with the equivalent interval cancer group (*χ*^2^=9.449, df=1, *P*=0.002).

Outcomes for Dukes\' D cancers
------------------------------

Two of 22 (4.5%) of Dukes\' D interval cancers and 3 of 21 (14.3%) of screen-detected cancers were diagnosed after the incident (second round) of FOB tests. There were no differences in gender, ASA grade, tumour location, or T stage observed between groups. There were significant differences in deprivation level (*χ*^2^=12.044, df=4, *P*=0.017) and rates of resective surgery (screen-detected 57.1% *vs* interval 22.7%, *χ*^2^=7.792, df=2, *P*=0.020) between groups. Although 11.4% of patients with an interval CRC died within the first 30 days post diagnosis compared with none of the patients with a screen-detected CRC, this was not statistically significant.

Survival for these groups was found to be significantly different, with screen-detected cancers having a better survival rate (log-rank Mantel--Cox *χ*^2^=8.322, df=1, *P*=0.04), as shown in [Figure 4](#fig4){ref-type="fig"}.

Multivariate analysis across Dukes\' stages
-------------------------------------------

[Table 3](#tbl3){ref-type="table"} shows the results of the Cox proportional hazards regression analysis of variables influencing survival of patients. Dukes\' stage, tumour location (HR 1.84, 95% CI 1.19--2.83, *P*=0.006 for proximal location) and diagnostic group (HR 0.45, 95% CI 0.29--0.69, *P*\<0.001 for screen-detected CRCs) were all found to have a significant impact on the survival of patients.

Discussion
==========

This study reports a significant difference in survival between screen-detected and interval cancer patients with Dukes\' C- and D-stage CRCs. Previous research has suggested that the earlier stage of screen-detected tumours is the explanation for the survival advantage over interval cancers, but this study questions whether this is the sole factor ([@bib21]; [@bib8]; [@bib15]). Of note, when compensating for stage of tumour on multivariate analysis, there is still a large influence from the diagnostic category, suggesting histological heterogeneity.

One compelling argument for the effects seen is that the results are solely due to lead-time bias. In other words, that both cohorts would have had the same survival outcome had they had been diagnosed through symptomatic services. However, it is equally plausible that there are biological differences between screen-detected and interval cancers that make some tumours bleed more readily and therefore be more likely to be detected by a FOBt. Reasons for differences in bleeding tendency have been postulated to be related to the extent of microerosion and a thin surface epithelium of lesions in relation to their surface area ([@bib23]), the location and overall size of the lesions ([@bib7]) and, the degree of invasion through the submucosa of malignant cells ([@bib10]). The FOB test has also previously been shown to have differential detection rates depending on location (but not stage) of cancer, as well as a dietary influence ([@bib11]; [@bib22]). Unfortunately, data relating to size and microscopic appearance are not routinely collected by either the BCSP or NORCCAG databases.

The timing of the FOBt is at a fixed point in relation to the age of the screenee, but uptake of the test may be influenced if they are experiencing lower GI symptoms, such as bleeding. Such symptoms have been found to be prevalent among those undergoing a screening colonoscopy ([@bib17]).

For Dukes\' C CRCs, no differences were found in the variables known to influence outcome such as patient comorbidity (using ASA grade as a surrogate), and deprivation level. All patients were engaged in the screening programme, potentially eliminating any difference in motivation or health behaviours. However, there was a difference between male and female proportions, with a greater proportion of men having a screen-detected cancer. The improved survival curve of screen-detected cancers is therefore contrary to the improved survival of women when adjusted for stage ([@bib3]).

There are several possibilities in explaining the survival difference observed for Dukes\' C CRCs. First, it may be due to the difference in tumour location. There have been three recent reports that have suggested that for left-sided colonic lesions, survival is better for stage 3 cancer (American Joint Commission on Cancer stage, with nodal involvement and worse for stage 2; [@bib12]; [@bib4]; [@bib24]). As there was a significantly greater proportion of left-sided cancers within the screen-detected cancer group (78% *vs* 61%, *P*=0.03), this may explain the superior survival curve. Further evidence to support this is that survival curves analysed by tumour site (for Dukes\' C cancers) are not significantly different (right-sided *P*=0.097, left-sided *P*=0.184).

Both groups had a similar mix of C1 and C2 stages but there was only a significant difference in survival for C2 tumours (*P*=0.002). In the interval cancer group, for Dukes\' C2 cancers, there was a significantly greater mean number of positive lymph nodes found (15 *vs* 4). An explanation for this may be that this subgroup of interval cancers was more aggressive in its regional lymph node spread, which is in turn consistent with the poorer outcomes for this group. This group may also have contained tumours that were associated with adverse histological features such as extramural lymphovascular invasion, tumour-associated lymphocytes, or peritoneal involvement which the NORCCAG database does not contain data upon ([@bib20]; [@bib13]). Alternatively, lead-time bias would have allowed more time for metastases for this subgroup to become apparent.

An alternative explanation for differences in outcomes for each stage of tumour, between interval and screen-detected groups is that, instead of interval cancer group being more aggressive, screen-detected cancers are more indolent than cancers detected symptomatically pre-screening. Interval CRCs might be expected to have a worse survival rate compared to a control group. However, as previously reported, the survival curves for interval cancers and control group cancers (non-screened population) are equivalent ([@bib8]). Therefore, the improved survival in the screen-detected group could be secondary to these tumours having a low potential for metastasis, and hence reducing the risk of a patient having micro-metastases or circulating tumour cells remaining *in situ* after initial cancer treatment.

Limitations of this research are in the subgroup analysis of C1 and C2 CRC groups, where small numbers make it difficult to draw any firm conclusions. The NORCCAG database does not contain data on the management of metastases of patients that present with Dukes\' D cancer. It is therefore not known whether there was a difference in resection rate for metastases between the two groups. If there was a higher rate of resection in the screen-detected group this might, at least partially, explain the survival advantage. Data regarding prior endoscopic treatment outwith the screening programme were not available. Although, it is likely that all study patients have had no previous endoscopic experience, as those who are enrolled on a surveillance programme are asked to discuss this with the programme ([@bib16]).

It is unknown whether the above results will be reproduced with the introduction of endoscopic screening, such as flexible sigmoidoscopy screening in the UK. However, a US study has shown similar findings with improved survival rates for patients detected through screening colonoscopy ([@bib1]). The implications of a biological difference in screen-detected cancers may influence future screening strategies that are based upon a tumour\'s propensity to bleed, against those that endoscopically screen a population.

The relationship between lead-time bias *vs* a difference in the biology of screen-detected and interval CRCs and the outcome of patients remains unknown, therefore a further detailed analysis of the biology of screen and post FOBt interval cancers is planned. This will help to answer questions regarding the nature and structure of these cancers, both on a macroscopic and microscopic level.
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###### Patient demographics, tumour details, management and outcome of screen, and interval cancers by Dukes\' stage

                                                        **Dukes\' stage A**   **Dukes\' stage B**   **Dukes\' stage C**   **Dukes\' stage D**                                                
  ----------------------------------------------------- --------------------- --------------------- --------------------- --------------------- -------------- -------------- -------------- --------------
  Mean age, years (s.e.m.)                              64.75 (0.28)          65.80 (0.46)          64.88 (0.35)          65.99 (0.39)          65.49 (0.32)   65.77 (0.38)   64.05 (0.71)   65.24 (0.45)
  **Gender**                                                                                                                                                                                 
   Male                                                 87 (69.6%)            20 (55.6%)            63 (77.8%)            34 (66.7%)            66 (74.2%)     31 (55.4%)     15 (71.4%)     29 (65.9%)
   Female                                               38 (30.4%)            16 (44.4%)            18 (22.2%)            17 (33.3%)            23 (25.8%)     25 (44.6%)     6 (28.6%)      15 (34.1%)
  **ASA grade**                                                                                                                                                                              
   1--2                                                 70 (77.8%)            19 (73.1%)            51 (77.3%)            37 (78.7%)            65 (85.5%)     35 (77.8%)     9 (75.0%)      9 (52.9%)
   3--5                                                 20 (22.2%)            7 (26.9%)             15 (22.7%)            10 (21.3%)            11 (14.5%)     10 (22.2%)     3 (25.0%)      8 (47.1%)
  **Index of multiple deprivation quintile category**                                                                                                                                        
   Most affluent                                        16 (12.8%)            10 (27.8%)            4 (4.9%)              8 (15.7%)             11 (12.4%)     9 (16.1%)      0 (0.0%)       3 (6.8%)
   2                                                    25 (20.0%)            3 (8.3%)              14 (17.3%)            6 (11.8%)             17 (19.1%)     11 (19.6%)     5 (23.8%)      5 (11.4%)
   3                                                    27 (21.6%)            9 (25.0%)             20 (24.7%)            15 (29.4%)            19 (21.3%)     15 (26.8%)     3 (14.3%)      13 (29.5%)
   4                                                    24 (19.2%)            6 (16.7%)             20 (24.7%)            10 (19.6%)            21 (23.6%)     12 (21.4%)     10 (47.6%)     7 (15.9%)
   Most deprived                                        33 (26.4%)            8 (22.2%)             23 (28.4%)            12 (23.5%)            21 (23.6%)     9 (16.1%)      3 (14.3%)      16 (36.4%)
  **Tumour location**                                                                                                                                                                        
   Distal to splenic flexure                            108 (86.4%)           30 (83.3%)            54 (66.7%)            29 (56.9%)            69 (77.5%)     34 (60.7%)     16 (76.2%)     30 (68.2%)
   Splenic flexure and proximal                         17 (13.6%)            6 (16.7%)             27 (33.3%)            22 (43.1%)            20 (22.5%)     22 (39.3%)     5 (23.8%)      14 (31.8%)
  **T stage**                                                                                                                                                                                
   pT1                                                  86 (68.8%)            22 (61.1%)                                                        6 (6.7%)       3 (5.4%)       0 (0.0%)       0 (0.0%)
   pT2                                                  39 (31.2%)            14 (38.9%)                                                        11 (12.4%)     4 (7.1%)       1 (8.3%)       0 (0.0%)
   pT3                                                                                              70 (86.4%)            36 (70.6%)            51 (57.3%)     28 (50.0%)     5 (41.7%)      4 (40.0%)
   pT4                                                                                              11 (13.6%)            15 (29.4%)            20 (22.5%)     21 (37.5%)     6 (50.0%)      6 (60.0%)
   pTx                                                                                                                                          1 (1.1%)       0 (0.0%)       0 (0.0%)       0 (0.0%)
  **Type of procedure**                                                                                                                                                                      
   Resective                                            87 (69.6%)            32 (88.9%)            81 (100.0%)           51 (100.0%)           89 (100.0%)    56 (100.0%)    12 (57.1%)     10 (22.7%)
   Local excision                                       38 (30.4%)            4 (11.1%)             0 (0.0%)              0 (0.0%)              0 (0.0%)       0 (0.0%)       0 (0.0%)       0 (0.0%)
   Palliative                                           0 (0.0%)              0 (0.0%)              0 (0.0%)              0 (0.0%)              0 (0.0%)       0 (0.0%)       3 (14.3%)      8 (18.2%)
   No procedure                                         0 (0.0%)              0 (0.0%)              0 (0.0%)              0 (0.0%)              0 (0.0%)       0 (0.0%)       6 (28.6%)      26 (59.1%)
  **30-Day mortality**                                                                                                                                                                       
   Yes                                                  0 (0.0%)              0 (0.0%)              0 (0.0%)              0 (0.0%)              1 (1.1%)       1 (1.8%)       0 (0.0%)       5 (11.4%)
   No                                                   125 (100.0%)          36 (100.0%)           81 (100.0%)           51 (100.0%)           88 (98.9%)     55 (98.2%)     21 (100.0%)    39 (88.6%)

Abbreviation: ASA=American Society of Anaesthesiologists.

###### Mean number of positive lymph nodes and total nodes harvested for each Dukes\' C stage

                                                                    **95% Confidence interval of the difference**           
  ------------ ---------------------- ---------------- ------------ ----------------------------------------------- ------- -------
  C1           Positive lymph nodes      2.9 (0.3)     3.6 (0.6)    −0.63                                           2.05    0.293
               Total lymph nodes         15.3 (0.8)    16.5 (1.2)   −1.61                                           4.14    0.383
               ***n*****=9**           ***n*****=7**                                                                         
  C2           Positive lymph nodes      3.9 (0.9)     14.6 (4.3)   2.25                                            19.12   0.017
               Total lymph nodes         13.0 (1.6)    20.3 (5.1)   −3.02                                           17.6    0.152
               ***n*****=89**          ***n*****=56**                                                                        
  C combined   Positive lymph nodes      3.0 (0.3)     5.0 (0.9)    0.43                                            3.53    0.013
               Total lymph nodes         15.0 (0.7)    17.0 (1.3)   −0.86                                           4.80    0.171

###### Cox regression multivariate analysis of variables affecting survival

                                                                **95% Confidence interval**           
  ----------------------------------------------------- ------- ----------------------------- ------- ---------
  Age (per year)                                        1.01    0.95                          1.08    0.730
  **Sex**                                                                                             
   Female                                               1.00                                           
   Male                                                 0.95    0.63                          1.43    0.806
  **Diagnostic category**                                                                             
   Interval                                             1.00                                           
   Screen-detected                                      0.45    0.29                          0.69    \<0.001
  **Index of multiple deprivation quintile category**                                                 
   Most affluent                                        1.00                                           
   2                                                    0.75    0.29                          1.92    0.549
   3                                                    1.02    0.44                          2.34    0.962
   4                                                    1.78    0.79                          4.02    0.168
   Most deprived                                        2.01    0.92                          4.40    0.079
  **ASA grade**                                                                                       
   ASA 1--2                                             1.00                                           
   ASA 3--5                                             1.56    0.90                          2.72    0.114
  **Tumour site**                                                                                     
  Distal to splenic flexure                             1.00                                           
  Splenic flexure and proximal                          1.84    1.19                          2.83    0.006
  **Dukes\' stage**                                                                                   
  Dukes\' A                                             1.00                                           
  Dukes\' B                                             3.85    1.41                          10.54   0.009
  Dukes\' C                                             6.51    2.49                          16.97   \<0.001
  Dukes\' D                                             35.30   13.57                         91.87   \<0.001

Abbreviation: ASA=American Society of Anaesthesiologists.
